iRhythm to Acquire VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care
iRhythm Holdings, Inc. (Nasdaq: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict and prevent disease, today announced that it and its wholly owned subsidiary, iRhythm Technologies, Inc., have entered into a definitive agreement to acquire Vital Connect, Inc. (“VitalConnect”), a privately held leader in wearable biosensor technology and […]
The Case for Value-Based Specialty Care: Carrum’s Playbook for Lower-Cost, Better-Outcome, White-Glove Care
Employers have spent years absorbing significant healthcare cost growth with few good options. Glucagon-like peptide-1 (“GLP-1”) drugs and specialty pharmacy get most of the headlines, but surgical and specialty medical care (for example, joint replacements, spinal fusions, bariatric surgery, cancer treatment) represent one of the largest line items in any self-insured employer’s health plan. Yet […]
Summit Spine & Joint Centers Acquires Southeast Neurology & Pain Management
Summit Spine & Joint Centers, one of the nation’s fastest-growing minimally invasive spine and interventional pain management platforms, announced the acquisition of Southeast Neurology & Pain Management (“SNPM”), a leading regional interventional pain management practice with clinic locations in Thomasville, GA, Tallahassee, FL, and Panama City, FL. The acquisition represents Summit’s third strategic practice acquisition […]
Mike Boggs Featured on “The Distribution” Podcast
Revelation Partners’ Managing Partner Mike Boggs is featured on The Distribution podcast, recorded live at the 2026 Venture Secondary Summit. Mike joined Justin Burden of Industry Ventures and host Brandon Sedloff for a wide-ranging conversation on the evolution of venture secondaries — from its origins as a tool for distressed sellers to its emergence as […]
Nouscom Receives U.S. FDA Fast Track Designation for NOUS-209, a Novel Immunotherapy for the Prevention of Lynch Syndrome-Associated Cancers
Nouscom, a clinical-stage biotech company developing next-generation immunotherapies to treat cancer at all stages, from early cancer interception to late-stage metastatic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to NOUS-209 for the prevention of Lynch Syndrome (LS)-associated cancers in LS carriers with genetically confirmed mismatch repair […]
Healthcare Secondaries Manager Revelation Partners Appoints Prashant Gangwal as Partner and CFO
Revelation Partners, the largest secondaries investment manager focused solely on private healthcare, has appointed Prashant Gangwal as partner and chief financial officer. Before joining Revelation Partners, Gangwal was chief financial officer of Altos Ventures, a San Francisco Bay Area-based registered investment advisor that partners with early to growth stage technology companies in consumer and enterprise […]
Medtronic announces intent to acquire SPR Therapeutics, expanding care options for people living with chronic pain
Medtronic plc (NYSE: MDT), a global healthcare technology leader, today announced its intent to acquire SPR Therapeutics, Inc. (SPR), a privately held medical technology company and a recognized leader in temporary, percutaneous peripheral nerve stimulation (PNS) therapies for chronic pain management. The transaction consists of an upfront cash payment of approximately $650 million for all the […]
Beyond the Middleman: The PBM Market at an Inflection Point
The Pharmacy Benefit Manager market is undergoing its most significant shift in years. Long-building employer frustration is now converging with rising pharmacy costs, new fiduciary accountability, and landmark regulatory reform — creating real openings for a new generation of platforms. In this white paper, we cover:
Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera
Eli Lilly and Company (NYSE: LLY) and Ajax Therapeutics, Inc. (“Ajax”), a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced a definitive agreement for Lilly to acquire Ajax. Ajax’s lead asset, AJ1-11095, is an investigational, once-daily oral, first-in-class Type II JAK2 inhibitor currently being evaluated in a Phase 1 […]
Click Therapeutics and Boehringer Ingelheim Announce Series D Investment and Funding to Advance Commercialization of CT-155
Boehringer Ingelheim and Click Therapeutics today announced a strategic agreement to support the commercialization of CT-155, an investigational prescription digital therapeutic that is being studied for the treatment of the experiential negative symptoms of schizophrenia in adults aged 18 years and older.3 Under the agreement, Boehringer will transfer full product responsibility, including all commercial and marketing […]